Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
19.43
+0.07 (0.36%)
Nov 5, 2024, 4:00 PM EST - Market closed

Company Description

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.

The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.

Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.

Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva, Inc.
Innoviva logo
Country United States
Founded 1996
IPO Date Oct 5, 2004
Industry Biotechnology
Sector Healthcare
Employees 112
CEO Pavel Raifeld

Contact Details

Address:
1350 Old Bayshore Highway, Suite 400
Burlingame, California 94010
United States
Phone 650 238 9600
Website inva.com

Stock Details

Ticker Symbol INVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001080014
CUSIP Number 45781M101
ISIN Number US45781M1018
Employer ID 94-3265960
SIC Code 2834

Key Executives

Name Position
Pavel Raifeld C.F.A. Chief Executive Officer
Stephen Basso M.B.A. Chief Financial Officer
Marianne Zhen CPA Chief Accounting Officer and Secretary
Patricia M. Drake Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc.

Latest SEC Filings

Date Type Title
Jul 31, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
May 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 13, 2024 8-K Current Report
May 9, 2024 ARS Filing
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
May 8, 2024 SC 13D General statement of acquisition of beneficial ownership
Apr 30, 2024 8-K Current Report